Acura Pharmaceuticals borrows $250,000

By Ted A. Knutson

Washington, Nov. 28 - Acura Pharmaceuticals, Inc. said Monday it borrowed $250,000 from lenders on Wednesday.

The loan was an increase to the $800,000 bridge loan dated Nov. 9, according to a company news release.

The lenders in the original agreement include Essex Woodlands Health Venture V, LP; Care Capital Investments II, LP; Care Capital Offshore Investments II, LP; Galen Partners III, LP; Galen Partners International III, LP; and Galen Employee Fund III, LP.

Palatine, Ill.-based Acura is a specialty pharmaceutical company engaged in research, development and manufacture of innovative and proprietary abuse deterrent, abuse resistant and tamper resistant formulations intended for use in orally administered opioid-containing prescription analgesic products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.